v3.26.1
Collaborative Research and Development Agreements - Schedule of Milestones Payable (Details) - Vanda Pharmaceuticals Inc
$ in Millions
6 Months Ended
Jun. 30, 2026
USD ($)
FDA Regulatory Approval For Marketing Of First Licensed Product In The USA For The Treatment Of Active Flares In GPP  
Disaggregation of Revenue [Line Items]  
Milestones that may be recognized in the future $ 5.0
Regulatory Approval For Marketing Of The First Licensed Product In The EU  
Disaggregation of Revenue [Line Items]  
Milestones that may be recognized in the future 5.0
Commercial Sales Milestone  
Disaggregation of Revenue [Line Items]  
Milestones that may be recognized in the future 25.0
Cumulative Milestones Recognized  
Disaggregation of Revenue [Line Items]  
Collaboration revenue 0.0
Milestones Yet To Be Recognized  
Disaggregation of Revenue [Line Items]  
Milestones that may be recognized in the future $ 35.0